Monday, November 2, 2026
26.5 C
Bengaluru

Platforms Are Owning the Patient While Pharma Waits

The future of experimental medicine is not simply a regulatory question. It is a question about who controls access, who pays for treatment, who generates evidence, and who bears the risk.

We spend too much time debating what will happen in healthcare.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

The Innovator’s Gene and the Generic’s Promise

A medicine must first be discovered. It must then...

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...

Topics

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...

Who Is Accountable for the Medicine in Your Hand?

The Accountability Gap: India’s Drug Regulatory System Your doctor prescribes...
spot_img

Related Articles

spot_imgspot_img